We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
PURPOSE Appropriate therapy for Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) -2 patients with advanced non-small-cell lung cancer ( NSCLC ) remains challenging . PS-2 patients on ECOG 1594 had a median survival ( MS ) of only 4.1 months and 1-year overall survival ( OS ) of 19 % . Three percent had grade 5 toxicity . PATIENTS AND METHODS ECOG 1599 , the first PS 2-specific , US cooperative group trial for treatment-naïve advanced NSCLC , r and omly assigned patients to dose-attenuated carboplatin/paclitaxel ( the least toxic regimen in ECOG 1594 ) or gemcitabine/cisplatin ( which yielded an MS of 7.9 months in PS-2 patients ) . Patients received either carboplatin ( area under the concentration-time curve , 6 ) and paclitaxel 200 mg/m2 every 3 weeks ( CbP ) or gemcitabine 1 g/m2 days 1 and 8 and cisplatin 60 mg/m2 day 1 every 3 weeks ( CG ) . RESULTS One hundred three patients were enrolled ; 100 proved eligible . Median age was 66 years ; 46 % had at least 5 % weight loss ; 88 % had stage IV or recurrent disease . Median number of cycles administered was three per arm . CbP featured more grade 3 neutropathy ( 10 % v 0 % ) and more grade > or = 3 neutropenia ( 59 % v 33 % ) , whereas CG yielded more grade 3 thrombocytopenia ( 33 % v 14 % ) , more grade 3 fatigue ( 22 % v 14 % ) , and more grade > or = 1 creatinine elevations ( 43 % v 6 % ) . One grade 5 toxicity , confined to the CbP arm , occurred . Response rate , time to progression , MS , and 1-year OS rates for CG and CbP , were 23 % , 4.8 months , 6.9 months , and 25 % , and 14 % , 4.2 months , 6.2 months , and 19 % , respectively . CONCLUSION Platinum-based combination chemotherapy for PS-2 patients with NSCLC is feasible with acceptable toxicity , but survival in these patients remains inferior to that of PS-0 to -1 patients
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV